688317.SH
Shanghai ZJ Bio-Tech Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 17.35
+3.71%Oct 14, 2026, 10:40 UTC
Zhejiang Bio completed its third share buyback of 2025, repurchasing 5.7569 million shares, or 3.03% of its total share capital, at an average price of CNY 19.11 per share for CNY 110 million excluding transaction fees.
Source:Aug 27, 2026, 08:08 UTC
ZhiJiang Bio announced its 2026 first-half results, reporting a net loss of 40.5894 million yuan, compared with a loss of 9.851 million yuan in the same period of 2025.
Source:Aug 19, 2026, 09:10 UTC
Zhi Jiang Bio announced that its monkeypox virus nucleic acid detection kit (fluorescent PCR method) obtained a Class III medical device registration certificate from China's NMPA, valid from August 17, 2026 to August 16, 2031, allowing use in China and other countries recognizing NMPA.
Source: